MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Felder, Mildred ^a   Kapur, Arvinder ^a   Gonzalez Bosquet, Jesus ^b   Horibata, Sachi ^a   Heintz, Joseph ^c   Albrecht, Ralph ^c   Fass, Lucas ^a   Kaur, Justanjyot ^a   Hu, Kevin ^d   Shojaei, Hadi ^a   Whelan, Rebecca J ^d   Patankar, Manish S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d OBERLIN COLLEGE   (United States)

Author keywords

CA125; Cancer biomarker; Immunesupression; Metastasis; MUC16; Natural killer cells; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CISPLATIN; DOXORUBICIN; MUCIN; OREGOVOMAB; PACLITAXEL; VEDOTIN; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MUC16 PROTEIN, HUMAN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; DRUG CONJUGATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; METASTASIS; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NATURAL KILLER CELL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902073103     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-129     Document Type: Review

References (177)

1. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 2005, 15:679-691. 10.1111/j.1525-1438.2005.00130.x, 16174214.
2. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih Ie M, Sibley P, Soletormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54:e11-e79. 10.1373/clinchem.2008.105601, 19042984.
3. Seltzer V, Drukker BH, Gillespie BW, Gossfeld LM, Grigsby PW, Harvey HA, Hendricks CB, Hummel S, Makuch RW, Monaco GP, Parham GP, Sawyers CL, West RJ, Alberts DS, Anderson B, Averette HE, Bast RC, Christian MC, Colombo N, Creasman WT, John P, Curtin JP, Gershenson DM, Hoskins WJ, Karlan BY, Kramer BS, Markman M, McGuire WP, Ozols RF, Pecorelli S, et al. NIH consensus conference: ovarian cancer: screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA 1995, 273:491-497. 10.1001/jama.1995.03520300065039, 7837369.
4. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004, 96:487-488.
5. Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet 2011, 284:221-227. 10.1007/s00404-010-1655-2, 3132454, 20803207.
6. Rustin GJ. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol 2011, 22(Suppl 8):viii45-viii48.
7. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B, Boman K, Park YC, Parekh T, Lebedinsky C, Gomez J, Monk BJ. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecol Oncol 2011, 122:350-355. 10.1016/j.ygyno.2011.04.005, 21546066.
8. Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol 2010, 22:498-502. 10.1097/CCO.0b013e32833ae8b6, 20498597.
9. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 2006, 103:212-218. 10.1016/j.ygyno.2006.02.026, 16677696.
10. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005, 17:399-411. 10.1016/j.clon.2005.05.009, 16149282.
11. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999, 17:501-508.
12. Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet 1996, 348:191-192.
13. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337. 10.1172/JCI110380, 370929, 7028788.
14. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309:883-887. 10.1056/NEJM198310133091503, 6310399.
15. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983, 2:275-285.
16. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 1983, 79:98-104.
17. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984, 64:703-707.
18. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998, 13:179-187.
19. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998, 44:1379-1380.
20. O'Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers 1998, 13:188-195.
21. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001, 22:348-366. 10.1159/000050638, 11786729.
22. Yin BW, Lloyd KO. Molecular cloning of the ca125 ovarian cancer antigen. identification as a new mucin, muc16. J Biol Chem 2001, 276:27371-27375. 10.1074/jbc.M103554200, 11369781.
23. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004, 279:9190-9198. 10.1074/jbc.M312372200, 14676194.
24. Hattrup CL, Gendler SJ. Structure and function of the cell surface (Tethered) Mucins. Annu Rev Physiol 2007, 70:431-457.
25. Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, Beaudin J, Piche A, Rancourt C. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011, 104:989-999. 10.1038/bjc.2011.34, 3065274, 21326240.
26. Bast RC, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 2011, 121:429-430. 10.1016/j.ygyno.2011.04.032, 21601106.
27. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, Bast RC, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995, 76:2004-2010. 10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G, 8634992.
28. Skates SJ, Pauler D, Jacobs I. Screening based on the risk of cancer calculation from Bayesian heirarchical changepoint and mixture models of longitudinal markers. J. Am. Statist. Assoc. 2001, 96:429-439.
29. Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V, Sjovall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 2000, 79:466-470. 10.1006/gyno.2000.5983, 11104621.
30. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC, Zurawski VR. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992, 80:14-18.
31. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993, 306:1030-1034. 10.1136/bmj.306.6884.1030, 1677033, 8490497.
32. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305:2295-2303. 10.1001/jama.2011.766, 21642681.
33. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS, Team PP. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009, 113:775-782. 10.1097/AOG.0b013e31819cda77, 2728067, 19305319.
34. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK, Team PP. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005, 193:1630-1639.
35. Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer 2013, 132:2127-2133. 10.1002/ijc.27909, 23065684.
36. Urban N. Screening for ovarian cancer: We now need a definitive randomised trial. BMJ 1999, 319:1317-1318. 10.1136/bmj.319.7221.1317, 1117062, 10567117.
37. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I. Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ 2008, 337:a2079. 10.1136/bmj.a2079, 2583394, 19008269.
38. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10:327-340. 10.1016/S1470-2045(09)70026-9, 19282241.
39. Menon U, Kalsi J, Jacobs I. The UKCTOCS experience-reasons for hope?. Int J Gynecol Cancer 2012, 22(Suppl 1):S18-S20.
40. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Surg Gynecol Obstet 1993, 176:310-314.
41. van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med 1992, 40:36-51.
42. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990, 1:301-302.
43. Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990, 39:26-33. 10.1016/0090-8258(90)90394-Z, 2227570.
44. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990, 97:922-929. 10.1111/j.1471-0528.1990.tb02448.x, 2223684.
45. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011, 118:280-288. 10.1097/AOG.0b013e318224fce2, 3594110, 21775843.
46. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46. 10.1016/j.ygyno.2008.08.031, 3594094, 18851871.
47. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408. 10.1016/j.ygyno.2007.10.017, 18061248.
48. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
49. Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 2013, 27:548-556.
50. Bast RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012, 22(Suppl 1):S5-S8. 3389992, 22543921.
51. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 2011, 4:375-383. 10.1158/1940-6207.CAPR-10-0193, 3057372, 21372037.
52. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011, 4:365-374. 10.1158/1940-6207.CAPR-10-0195, 3085251, 21372036.
53. Jacobs I, Menon U. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res (Phila) 2011, 4:299-302. 10.1158/1940-6207.CAPR-11-0048, 21372028.
54. Diamandis EP, Bast RC, Gold P, Chu TM, Magnani JL. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clin Chem 2013, 59:22-31. 10.1373/clinchem.2012.187047, 3983776, 23204222.
55. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984, 148:1057-1058.
56. O'Brien TJ, Raymond LM, Bannon GA, Ford DH, Hardardottir H, Miller FC, Quirk JG. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 1991, 165:1857-1864.
57. Lloyd KO, Yin BW, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. Int J Cancer 1997, 71:842-850. 10.1002/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8, 9180155.
58. Nap M, Vitali A, Nustad K, Bast RC, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Bormer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarstrom S, Kenemans P, Hilgers J. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 1996, 17:325-331.
59. Nustad K, Bast RC, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Bormer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarstrom S, Kenemans P, Hilgers J. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop: International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996, 17:196-219. 10.1159/000217982, 8685601.
60. Nustad K, Lebedin Y, Lloyd KO, Shigemasa K, de Bruijn HW, Jansson B, Nilsson O, Olsen KH, O'Brien TJ. Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop. Tumour Biol 2002, 23:303-314. 10.1159/000068570, 12595747.
61. Warren DJ, Nustad K, Beard JB, O'Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumour Biol 2009, 30:51-60. 10.1159/000209988, 19321947.
62. O'Brien TJ, Hardin JW, Bannon GA, Norris JS, Quirk JG. CA 125 antigen in human amniotic fluid and fetal membranes. Am J Obstet Gynecol 1986, 155:50-55.
63. Hanisch FG, Uhlenbruck G, Peter-Katalinic J, Egge H. Structural studies on oncofetal carbohydrate antigens (Ca 19-9, Ca 50, and Ca 125) carried by O-linked sialyloligosaccharides on human amniotic mucins. Carbohydr Res 1988, 178:29-47. 10.1016/0008-6215(88)80100-9, 3191509.
64. Davis HM, Zurawski VR, Bast RC, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 1986, 46:6143-6148.
65. Van Lenten L, Ashwell G. Studies on the chemical and enzymatic modification of glycoproteins. A general method for the tritiation of sialic acid-containing glycoproteins. J Biol Chem 1971, 246:1889-1894.
66. Ozgur K, Patankar MS, Oehninger S, Clark GF. Direct evidence for the involvement of carbohydrate sequences in human sperm-zona pellucida binding. Mol Hum Reprod 1998, 4:318-324. 10.1093/molehr/4.4.318, 9620830.
67. Lloyd KO, Yin BW. Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3. Tumour Biol 2001, 22:77-82. 10.1159/000050600, 11125279.
68. Quirk JG, Brunson GL, Long CA, Bannon GA, Sanders MM, O'Brien TJ. CA 125 in tissues and amniotic fluid during pregnancy. Am J Obstet Gynecol 1988, 159:644-649.
69. Hardardottir H, Parmley TH, Quirk JG, Sanders MM, Miller FC, O'Brien TJ. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 1990, 163:1925-1931.
70. Fendrick JL, Staley KA, Gee MK, McDougald SR, Quirk JG, O'Brien TJ. Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line. Tumour Biol 1993, 14:310-318. 10.1159/000217844, 8235310.
71. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N- terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002, 23:154-169. 10.1159/000064032, 12218296.
72. Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002, 98:737-740. 10.1002/ijc.10250, 11920644.
73. Konishi I, Fendrick JL, Parmley TH, Quirk JG, O'Brien TJ. Epidermal growth factor enhances secretion of the ovarian tumor- associated cancer antigen CA125 from the human amnion WISH cell line. J Soc Gynecol Investig 1994, 1:89-96.
74. Fendrick JL, Konishi I, Geary SM, Parmley TH, Quirk JG, O'Brien TJ. CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 1997, 18:278-289. 10.1159/000218041, 9276028.
75. Bressan A, Bozzo F, Maggi CA, Binaschi M. OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain. Dis Markers 2013, 34:257-267. 10.1155/2013/917898, 3810124, 23396293.
76. Berman ZT, Moore LJ, Knudson KE, Whelan RJ. Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16). Tumour Biol 2010, 31:495-502. 10.1007/s13277-010-0062-4, 20563897.
77. Bork P, Patthy L. The SEA module: a new extracellular domain associated with O-glycosylation. Protein Sci 1995, 4:1421-1425. 10.1002/pro.5560040716, 2143162, 7670383.
78. Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, Seki E, Matsuda T, Motoda Y, Kobayashi A, Hiroyasu F, Shirouzu M, Terada T, Hayami N, Ishizuka Y, Shinya N, Tatsuguchi A, Yoshida M, Hirota H, Matsuo Y, Tani K, Arakawa T, Carninci P, Kawai J, Hayashizaki Y, Kigawa T, Yokoyama S. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem 2004, 279:13174-13182. 10.1074/jbc.M309417200, 14764598.
79. Laver WG, Air GM, Webster RG, Smith-Gill SJ. Epitopes on protein antigens: misconceptions and realities. Cell 1990, 61:553-556. 10.1016/0092-8674(90)90464-P, 1693095.
80. Kui Wong N, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 2003, 278:28619-28634. 10.1074/jbc.M302741200, 12734200.
81. Chen K, Gentry-Maharaj A, Burnell M, Steentoft C, Marcos-Silva L, Mandel U, Jacobs I, Dawnay A, Menon U, Blixt O. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res 2013, 12:1408-1418. 10.1021/pr3010474, 23360124.
82. Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, Kitawaki J, Nakanishi H, Narimatsu H, Nakada H. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer 2012, 22:531-538. 10.1097/IGC.0b013e3182473292, 22367369.
83. Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. Exploring the glycosylation of serum CA125. Int J Mol Sci 2013, 14:15636-15654. 10.3390/ijms140815636, 3759877, 23896595.
84. Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark 2008, 4:35-42.
85. Mitic N, Milutinovic B, Jankovic M. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs). Dis Markers 2012, 32:187-194. 10.1155/2012/309203, 3826874, 22377735.
86. Milutinovic B, Mitic N, Jankovic M. Identification of pregnancy-associated CA125-reactive protein as a carbohydrate-binding immunoglobulin G. Arch Biochem Biophys 2010, 499:69-76. 10.1016/j.abb.2010.05.011, 20488159.
87. Jankovic MM, Milutinovic BS. Pregnancy-associated CA125 antigen as mucin: evaluation of ferning morphology. Mol Hum Reprod 2007, 13:405-408. 10.1093/molehr/gam022, 17449537.
88. Jankovic MM, Tapuskovic BS. Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen. Hum Reprod 2005, 20:2632-2638. 10.1093/humrep/dei095, 15905287.
89. Wahrenbrock MG, Varki A. Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the " tip of the iceberg" ?. Cancer Res 2006, 66:2433-2441. 10.1158/0008-5472.CAN-05-3851, 16489050.
90. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, Gogineni A, Ross S, Polakis P, Mallet W. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 2007, 67:4924-4932. 10.1158/0008-5472.CAN-06-4512, 17510422.
91. Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, Spriggs DR. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl Immunohistochem Mol Morphol 2010, 18:462-472.
92. Kerschner JE. Mucin gene expression in human middle ear epithelium. Laryngoscope 2007, 117:1666-1676. 10.1097/MLG.0b013e31806db531, 17667140.
93. Davies JR, Kirkham S, Svitacheva N, Thornton DJ, Carlstedt I. MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells. Int J Biochem Cell Biol 2007, 39:1943-1954. 10.1016/j.biocel.2007.05.013, 17604678.
94. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V, Gipson IK. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2007, 48:4509-4518. 10.1167/iovs.07-0430, 17898272.
95. Hori Y, Spurr-Michaud SJ, Russo CL, Argueso P, Gipson IK. Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci 2005, 46:4050-4061. 10.1167/iovs.05-0627, 1473963, 16249480.
96. Argueso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci 2003, 44:2487-2495. 10.1167/iovs.02-0862, 12766047.
97. Govindarajan B, Gipson IK. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res 2010, 90:655-663. 10.1016/j.exer.2010.02.014, 2893012, 20223235.
98. Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene 2006, 373:28-34.
99. Govindarajan B, Menon BB, Spurr-Michaud S, Rastogi K, Gilmore MS, Argueso P, Gipson IK. A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16 from the epithelial glycocalyx barrier. PLoS One 2012, 7:e32418. 10.1371/journal.pone.0032418, 3296694, 22412870.
100. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Gipson IK. Release of membrane-associated mucins from ocular surface epithelia. Invest Ophthalmol Vis Sci 2008, 49:1864-1871. 10.1167/iovs.07-1081, 2622730, 18436821.
101. Govindarajan B, Gipson IK. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res 2010, 90:655-663. 10.1016/j.exer.2010.02.014, 2893012, 20223235.
102. Argueso P, Tisdale A, Spurr-Michaud S, Sumiyoshi M, Gipson IK. Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye. Invest Ophthalmol Vis Sci 2006, 47:113-119. 10.1167/iovs.05-0735, 1351157, 16384952.
103. Argueso P, Guzman-Aranguez A, Mantelli F, Cao Z, Ricciuto J, Panjwani N. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem 2009, 284:23037-23045. 10.1074/jbc.M109.033332, 2755710, 19556244.
104. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One 2009, 4:e4675. 10.1371/journal.pone.0004675, 2650410, 19262696.
105. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 2008, 76:1081-1092. 10.1111/j.1432-0436.2008.00295.x, 2593124, 18637025.
106. Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, Patankar MS. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 2010, 9:11. 10.1186/1476-4598-9-11, 2818693, 20089172.
107. Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL. The human natural killer cell immune synapse. Proc Natl Acad Sci U S A 1999, 96:15062-15067. 10.1073/pnas.96.26.15062, 24773, 10611338.
108. Orange JS. The lytic NK cell immunological synapse and sequential steps in its formation. Adv Exp Med Biol 2007, 601:225-233. 10.1007/978-0-387-72005-0_23, 17713009.
109. Mace EM, Orange JS. New views of the human NK cell immunological synapse: recent advances enabled by super- and high-resolution imaging techniques. Front Immunol 2012, 3:421. 3540402, 23316204.
110. Jentoft N. Why are proteins O-glycosylated?. Trends Biochem Sci 1990, 15:291-294. 10.1016/0968-0004(90)90014-3, 2204153.
111. Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res 1999, 59:2229-2236.
112. Belisle JA, Horibata S, Gubbels JA, Petrie S, Kapur A, Andre S, Gabius HJ, Rancourt C, Connor J, Paulson JC, Patankar MS. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 2010, 9:118. 10.1186/1476-4598-9-118, 2890604, 20497550.
113. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502. 2669298, 18425106.
114. Crocker PR, Clark EA, Filbin M, Gordon S, Jones Y, Kehrl JH, Kelm S, Le Douarin N, Powell L, Roder J, Schnaar RL, Sgroi DC, Stamenkovic K, Schauer R, Schachner M, van den Berg TK, van der Merwe PA, Watt SM, Varki A. Siglecs: a family of sialic-acid binding lectins [letter]. Glycobiology 1998, 8:v.
115. Angata T, Varki A. Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology 2000, 10:431-438. 10.1093/glycob/10.4.431, 10764831.
116. Zhang JQ, Nicoll G, Jones C, Crocker PR. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem 2000, 275:22121-22126. 10.1074/jbc.M002788200, 10801862.
117. Crocker PR, Varki A. Siglecs in the immune system. Immunology 2001, 103:137-145. 10.1046/j.0019-2805.2001.01241.x, 1783234, 11412300.
118. Varki A, Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 2006, 16:1R-27R. 10.1093/glycob/cwj126, 16014749.
119. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007, 7:255-266. 10.1038/nri2056, 17380156.
120. Yamaji T, Teranishi T, Alphey MS, Crocker PR, Hashimoto Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha2,8-disialyl and branched alpha2,6-sialyl residues: a comparison with Siglec-9. J Biol Chem 2001, 10:6324-6332.
121. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004, 173:6841-6849. 10.4049/jimmunol.173.11.6841, 15557178.
122. Madsen CB, Lavrsen K, Steentoft C, Vester-Christensen MB, Clausen H, Wandall HH, Pedersen AE. Glycan elongation beyond the mucin associated tn antigen protects tumor cells from immune-mediated killing. PLoS One 2013, 8:e72413. 10.1371/journal.pone.0072413, 3765166, 24039759.
123. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998. 10.1038/ni1102-991, 12407406.
124. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148. 10.1016/j.immuni.2004.07.017, 15308095.
125. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
126. Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem 2013, 13:276-280. 10.2174/1871520611313020014, 3568227, 22721387.
127. Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 2013, 3:1870. 3660778, 23694968.
128. Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, Yamaue H. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 2012, 103:739-746. 10.1111/j.1349-7006.2012.02214.x, 22320398.
129. Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, Batra SK, Yonezawa S. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology 2012, 79:101-106. 10.1159/000335164, 22286058.
130. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS. Mesothelin-MUC16 binding is a high affinit: N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006, 5:50. 10.1186/1476-4598-5-50, 1635730, 17067392.
131. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett 2006, 247:130-136. 2734268, 16677756.
132. Sathyanarayana BK, Hahn Y, Patankar MS, Pastan I, Lee B. Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. BMC Struct Biol 2009, 9:1. 10.1186/1472-6807-9-1, 2628672, 19128473.
133. Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 2010, 68:455-459. 10.1016/j.lungcan.2009.07.016, 2864325, 19744744.
134. Chopra A. 111In-Labeled CHX-A''-DTPA-conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin. Molecular Imaging and Contrast Agent Database (MICAD) 2004, MD: Bethesda.
135. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010, 16:6132-6138. 10.1158/1078-0432.CCR-10-2275, 3057907, 21037025.
136. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008, 44:46-53. 10.1016/j.ejca.2007.08.028, 2265108, 17945478.
137. Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009, 284:3739-3749. 10.1074/jbc.M806776200, 2635045, 19075018.
138. Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, Ho M. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer Educ 2011, 2:280-291.
139. Chen SH, Dallas MR, Balzer EM, Konstantopoulos K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J 2012, 26:1349-1359. 10.1096/fj.11-195669, 3289508, 22159147.
140. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 1992, 267:6171-6177.
141. Hilkens J, Buijs F. Biosynthesis of MAM-6, an epithelial sialomucin. Evidence for involvement of a rare proteolytic cleavage step in the endoplasmic reticulum. J Biol Chem 1988, 263:4215-4222.
142. Komatsu M, Arango ME, Carraway KL. Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis. Biochem J 2002, 368:41-48. 10.1042/BJ20020862, 1222983, 12186632.
143. Albrecht H, Carraway KL. MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother Radiopharm 2011, 26:261-271. 10.1089/cbr.2011.1017, 3128783, 21728842.
144. Senapati S, Das S, Batra SK. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 2010, 35:236-245. 10.1016/j.tibs.2009.10.003, 3030310, 19913432.
145. Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, Carraway KL, Kufe D. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 2001, 276:35239-35242. 10.1074/jbc.C100359200, 11483589.
146. Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S, Kufe D. MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther 2008, 7:1959-1967. 10.4161/cbt.7.12.6956, 3023907, 18981727.
147. Boivin M, Lane D, Piche A, Rancourt C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 2009, 115:407-413. 10.1016/j.ygyno.2009.08.007, 19747716.
148. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piche A, Rancourt C. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011, 121:434-443. 10.1016/j.ygyno.2011.02.020, 21421261.
149. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, Lele SM, Batra SK. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012, 31:805-817. 10.1038/onc.2011.297, 3288594, 21785467.
150. Reinartz S, Failer S, Schuell T, Wagner U. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer 2011, 48:1558-1569.
151. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001, 7:2396-2404.
152. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008, 118:1367-1379. 10.1172/JCI33775, 2267016, 18340378.
153. Akita K, Tanaka M, Tanida S, Mori Y, Toda M, Nakada H. CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion. Eur J Cell Biol 2013, 92:257-263. 10.1016/j.ejcb.2013.10.005, 24246580.
154. Cancer Genome Atlas Research N Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. 10.1038/nature10166, 3163504, 21720365, Cancer Genome Atlas Research N.
155. Radhakrishnan P, Mohr AM, Grandgenett PM, Steele MM, Batra SK, Hollingsworth MA. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. PLoS One 2013, 8:e73356. 10.1371/journal.pone.0073356, 3808362, 24204560.
156. Baum RP, Hertel A, Baew-Christow T, Noujaim AA, Hor G. A novel Tc-99m labeled monoclonal antibody against CA125 (B43.13) for radioimmunodetection pf ovarian cancer-initial results. Nuclear Medicine 1992, 670-672. New York: Schattuer, Schmidt HAE, Stuttgart RH.
157. Mobus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003, 189:28-36.
158. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 2001, 16:187-203. 10.1089/10849780152389384, 11471484.
159. Schultes BC, Zhang C, Xue LY, Noujaim AA, Madiyalakan R. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model. Hybridoma 1999, 18:47-55. 10.1089/hyb.1999.18.47, 10211788.
160. Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 1998, 46:201-212. 10.1007/s002620050479, 9671143.
161. Ma J, Samuel J, Kwon GS, Noujaim AA, Madiyalakan R. Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres. Cancer Immunol Immunother 1998, 47:13-20. 10.1007/s002620050499, 9755874.
162. Reinsberg J, Krebs D. Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13?. Hybridoma 1997, 16:59-63. 10.1089/hyb.1997.16.59, 9085130.
163. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hor G, Noujaim AA. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 1995, 14:199-203. 10.1089/hyb.1995.14.199, 7590780.
164. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, Hor G. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994, 73:1121-1125. 10.1002/1097-0142(19940201)73:3+<1121::AID-CNCR2820731353>3.0.CO;2-Q, 8306256.
165. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hor G. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 1993, 12:583-589. 10.1089/hyb.1993.12.583, 8300134.
166. Berek JS. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther 2004, 4:1159-1165. 10.1517/14712598.4.7.1159, 15268682.
167. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004, 22:3507-3516. 10.1200/JCO.2004.09.016, 15337799.
168. Reinartz S, Kohler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Mobus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004, 10:1580-1587. 10.1158/1078-0432.CCR-03-0056, 15014007.
169. Reinartz S, Hombach A, Kohler S, Schlebusch H, Wallwiener D, Abken H, Wagner U. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res 2003, 63:3234-3240.
170. Reinartz S, Wagner U, Giffels P, Gruenn U, Schlebusch H, Wallwiener D. Immunological properties of a single-chain fragment of the anti- idiotypic antibody ACA125. Cancer Immunol Immunother 2000, 49:186-192. 10.1007/s002620000126, 10941901.
171. Reinartz S, Boerner H, Koehler S, Von Ruecker A, Schlebusch H, Wagner U. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report. Hybridoma 1999, 18:41-45. 10.1089/hyb.1999.18.41, 10211787.
172. Wagner U, Schlebusch H, Kohler S, Schmolling J, Grunn U, Krebs D. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 1997, 16:33-40. 10.1089/hyb.1997.16.33, 9085126.
173. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006, 12:5503-5510. 10.1158/1078-0432.CCR-05-2670, 17000686.
174. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study. J Clin Oncol 2013, 31:1554-1561. 10.1200/JCO.2012.46.4057, 23478059.
175. Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, du Bois A. Abagovomab for ovarian cancer. Expert Opin Biol Ther 2011, 11:395-403. 10.1517/14712598.2011.553598, 21241213.
176. Grisham RN, Berek J, Pfisterer J, Sabbatini P. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy 2011, 3:153-162. 10.2217/imt.10.100, 3221001, 21322756.
177. Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 2007, 122:418-429. 10.1111/j.1365-2567.2007.02660.x, 2266014, 17617155.